Bicara Therapeutics Files IPO Amendment
Ticker: BCAX · Form: S-1/A · Filed: Sep 3, 2024 · CIK: 2023658
| Field | Detail |
|---|---|
| Company | Bicara Therapeutics Inc. (BCAX) |
| Form Type | S-1/A |
| Filed Date | Sep 3, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: ipo, sec-filing, pharmaceutical
TL;DR
Bicara Therapeutics IPO filing updated. Going public soon.
AI Summary
Bicara Therapeutics Inc. filed an S-1/A amendment on September 3, 2024, for its initial public offering. The company, located at 116 Huntington Avenue, Suite 703, Boston, MA 02116, is seeking to register its securities under the Securities Act of 1933. Claire Mazumdar is the CEO and Lara Meisner is the Chief Legal Officer.
Why It Matters
This filing indicates Bicara Therapeutics is moving forward with its plan to become a publicly traded company, which could provide capital for its pharmaceutical development efforts.
Risk Assessment
Risk Level: medium — As a pre-IPO company, Bicara Therapeutics faces inherent risks associated with market conditions, regulatory approvals, and the success of its drug development pipeline.
Key Numbers
- 23 — Public Document Count (Indicates the volume of documents associated with this filing.)
Key Players & Entities
- Bicara Therapeutics Inc. (company) — Registrant
- September 3, 2024 (date) — Filing Date
- 116 Huntington Avenue, Suite 703, Boston, MA 02116 (address) — Principal Executive Offices
- Claire Mazumdar (person) — Chief Executive Officer
- Lara Meisner (person) — Chief Legal Officer and Corporate Secretary
- 333-281722 (registration_number) — SEC Registration Number
FAQ
What is the purpose of this S-1/A filing?
This is an Amendment No. 1 to a Form S-1 Registration Statement, indicating Bicara Therapeutics Inc. is updating its initial filing for its proposed initial public offering.
When was this filing submitted?
The filing was submitted on September 3, 2024.
Where is Bicara Therapeutics Inc. headquartered?
Bicara Therapeutics Inc.'s principal executive offices are located at 116 Huntington Avenue, Suite 703, Boston, MA 02116.
Who are the key executives mentioned in the filing?
Claire Mazumdar is the Chief Executive Officer, and Lara Meisner is the Chief Legal Officer and Corporate Secretary.
What is the SEC file number for this registration?
The SEC file number is 333-281722.
Filing Stats: 4,492 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2024-09-03 07:26:34
Filing Documents
- d821336ds1a.htm (S-1/A) — 2389KB
- d821336dex231.htm (EX-23.1) — 1KB
- g821336g00a08.jpg (GRAPHIC) — 161KB
- g821336g00q02.jpg (GRAPHIC) — 217KB
- g821336g01r87.jpg (GRAPHIC) — 84KB
- g821336g05g18.jpg (GRAPHIC) — 84KB
- g821336g10k10.jpg (GRAPHIC) — 147KB
- g821336g10r10.jpg (GRAPHIC) — 194KB
- g821336g12w20.jpg (GRAPHIC) — 239KB
- g821336g14t99.jpg (GRAPHIC) — 148KB
- g821336g24l67.jpg (GRAPHIC) — 194KB
- g821336g37a01.jpg (GRAPHIC) — 32KB
- g821336g41g41.jpg (GRAPHIC) — 173KB
- g821336g41j07.jpg (GRAPHIC) — 146KB
- g821336g48g48.jpg (GRAPHIC) — 64KB
- g821336g61i92.jpg (GRAPHIC) — 151KB
- g821336g69p26.jpg (GRAPHIC) — 120KB
- g821336g71t91.jpg (GRAPHIC) — 95KB
- g821336g82t28.jpg (GRAPHIC) — 38KB
- g821336g82t29.jpg (GRAPHIC) — 90KB
- g821336g82t30.jpg (GRAPHIC) — 100KB
- g821336g89p15.jpg (GRAPHIC) — 178KB
- g821336g92o32.jpg (GRAPHIC) — 51KB
- 0001193125-24-211537.txt ( ) — 6065KB
Risk Factors
Risk Factors 13 Special Note Regarding Forward-looking Statements 77
Use Of Proceeds
Use Of Proceeds 79 Dividend Policy 81 Capitalization 82
Managements Discussion and Analysis of Financial Condition and Results
Managements Discussion and Analysis of Financial Condition and Results of Operations 87
Business
Business 105 Management 152
Executive Compensation
Executive Compensation 163 Director Compensation 178 Certain Relationships and Related Party Transactions 181 Principal Stockholders 188
Description of Capital Stock
Description of Capital Stock 192 Shares Eligible For Future Sale 198 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders of Common Stock 200
Underwriting
Underwriting 204 Legal Matters 213 Experts 213 Where You Can Find More Information 213 Index to Financial Statements F-1 Through and including, 2024 (the 25 th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of the date on the front cover of this prospectus, regardless of its time delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We own various U.S. federal trademark applications, registered and unregistered trademarks, and trade names including our company name. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols ® and , but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. F